Regeneron and Sanofi Report the EC Approval of Dupixent (Dupilumab) for Chronic Spontaneous Urticaria (CSU)

Why It Matters

The approval introduces the first biologic therapy for pediatric CSU in Europe, addressing a sizable unmet need and creating a new revenue stream. It also positions Dupixent ahead of U.S. clearance, strengthening its competitive edge against anti‑IgE agents.

Key Takeaways

• EC greenlights Dupixent for children 2‑11 with refractory CSU.
• Phase‑III trials showed significant UAS7 score reductions at 24 weeks.
• US supplemental BLA for pediatric CSU now under review.
• Expands Dupixent’s indication portfolio beyond asthma and atopic dermatitis.

Pulse Analysis

Chronic spontaneous urticaria (CSU) affects millions worldwide, with children often experiencing persistent hives and itching despite standard antihistamine therapy. The condition not only diminishes quality of life but also imposes indirect costs through missed school and caregiver burden. Dupixent, an IL‑4Rα antagonist, modulates the type‑2 inflammatory pathway implicated in CSU, offering a mechanistic advantage over traditional antihistamines and anti‑IgE treatments that target downstream effects.

The European Commission’s approval rests on robust data from the LIBERTY‑CUPID and CUPIDKids Phase‑III programs. Both studies met primary endpoints, showing statistically significant drops in the Urticaria Activity Score (UAS7) and higher proportions of patients achieving well‑controlled disease or complete response after 24 weeks of therapy. Importantly, the trials focused on antihistamine‑refractory patients who were naïve to anti‑IgE therapy, highlighting Dupixent’s potential as a first‑line biologic option in this subgroup. The U.S. supplemental BLA acceptance signals regulatory alignment and suggests a near‑term launch pending FDA decision.

From a commercial perspective, the new pediatric indication expands Dupixent’s addressable market by millions of patients and diversifies revenue beyond its established uses in atopic dermatitis, asthma, and chronic rhinosinusitis. The move also pre‑empts competitors such as omalizumab, which currently dominate the adult CSU space but lack pediatric labeling. As insurers evaluate cost‑effectiveness, the demonstrated clinical benefits may drive favorable formulary placement, accelerating uptake. Looking ahead, the approval sets a precedent for further biologic expansions into other pediatric allergic diseases, reinforcing Regeneron and Sanofi’s strategic focus on immune‑modulating therapies.